LEO Pharma Introduces Larger 120g Package Size of Taclonex (calcipotriene and betamethasone dipropionate) Topical Suspension
LEO Pharma Inc., a U.S. subsidiary of LEO Pharma A/S, announced it has launched a 120g package size of Taclonex (calcipotriene and betamethasone dipropionate) Topical Suspension, 0.005 percent/0.064 percent for the treatment of plaque psoriasis.
According to a release, Taclonex Topical Suspension is a first- line single treatment indicated for treatment of both scalp and body plaque psoriasis for up to eight weeks. Created with patient satisfaction and continued convenience in mind, this package offers patients a larger size to treat plaque psoriasis.
According to the company, psoriasis is a non-contagious, chronic disease of the immune system that affects an estimated 125 million people worldwide. The most common form, which affects roughly 80 percent of people who have the condition, is plaque psoriasis (psoriasis vulgaris). It is characterized by patches of raised, reddish skin covered with silvery-white scales. Up to 80 percent of patients have both scalp and body psoriasis. Since the indication for Taclonex Topical Suspension has recently expanded, patients are able to treat both scalp and body plaque psoriasis with one product.
"At LEO, we are committed to helping people achieve healthy skin," said John Koconis, president and chief executive officer of LEO Pharma Inc. "With the 120g size of Taclonex Topical Suspension, we have created a patient-friendly offering of the larger pack size."
Taclonex Topical Suspension is a once-daily, topical treatment that combines efficacy and safety profile of two active ingredients, a vitamin D analog (calcipotriene) and a corticosteroid (betamethasone dipropionate). Taclonex Topical Suspension requires only one prescription for treatment of both scalp and body plaque psoriasis.
"A once-daily application makes Taclonex Topical Suspension an effective, first-line choice of treatment for a significant number of psoriasis patients, with positive clinical results seen in a recent eight-week study," said Dr. Alan Menter, founder of the International Psoriasis Foundation. "In addition to its prior approval for use on the scalp, it has been shown to be safe and effective for use on the body, and this larger size allows for increased individualization and versatility in allocation of a patient's treatment."
LEO Pharma Inc. is a subsidiary of LEO Pharma A/S
LEO Pharma A/S is an independent, research-based pharmaceutical company.
((Comments on this story may be sent to email@example.com))